About Chronic Lymphocytic Leukemia

Overview and Types

If you have been diagnosed with chronic lymphocytic leukemia or worried about it, you likely have a lot of questions. Learning some basics is a good place to start.

- **What Is Chronic Lymphocytic Leukemia?**

Research and Statistics

See the latest estimates for new cases of chronic lymphocytic leukemia and deaths in the US and what research is currently being done.

- **Key Statistics for Chronic Lymphocytic Leukemia**
- **What's New in Chronic Lymphocytic Leukemia Research and Treatment?**

What Is Chronic Lymphocytic Leukemia?

Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the body. To learn more about how cancers start and spread, see **What Is Cancer?**

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from cells that become certain **white blood cells** (called **lymphocytes**) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood.

In CLL, the leukemia cells often build up slowly over time, and many people don't have any symptoms for at least a few years. In time, the cells can spread to other parts of the body, including the lymph nodes, liver, and spleen.
What is leukemia?

Leukemia is a cancer that starts in the blood-forming cells of the bone marrow. When one of these cells changes and becomes a leukemia cell, it no longer matures normally. Often, it divides to make new cells faster than normal. Leukemia cells also don't die when they should. This allows them to build up in the bone marrow, crowding out normal cells. At some point, leukemia cells leave the bone marrow and spill into the bloodstream, often causing the number of white blood cells in the blood to increase. Once in the blood, leukemia cells can spread to other organs, where they can prevent other cells in the body from functioning normally.

Leukemia is different from other types of cancer that start in organs like the lungs, colon, or breast and then spread to the bone marrow. Cancers that start elsewhere and then spread to the bone marrow are not leukemia.

Not all leukemias are the same. Knowing the specific type of leukemia helps doctors better predict each patient’s prognosis (outlook) and select the best treatment.

What is a chronic leukemia?

Whether leukemia is acute or chronic depends on whether most of the abnormal cells are immature (and are more like stem cells) or mature (and are like normal white blood cells).

In chronic leukemia, the cells can mature partly but not completely. These cells may look fairly normal, but they are not. They generally do not fight infection as well as normal white blood cells do. The leukemia cells survive longer than normal cells, and build up, crowding out normal cells in the bone marrow. Chronic leukemias can take a long time before they cause problems, and most people can live for many years. But chronic leukemias are generally harder to cure than acute leukemias.

What is a lymphocytic leukemia?

Whether leukemia is myeloid or lymphocytic depends on which bone marrow cells the cancer starts in.

Lymphocytic leukemias (also known as lymphoid or lymphoblastic leukemia) start in the cells that become lymphocytes. Lymphomas are also cancers that start in those cells. The main difference between lymphocytic leukemias and lymphomas is that in
leukemia, the cancer cell is mainly in the bone marrow and blood, while in lymphoma it tends to be in lymph nodes and other tissues.

Are there different types of CLL?

Doctors have found that there seem to be 2 different kinds of CLL:

- One kind of CLL grows very slowly and so it may take a long time before the patient needs treatment.
- The other kind of CLL grows faster and is a more serious disease.

The leukemia cells from these 2 types look alike, but lab tests can tell the difference between them. The tests look for proteins called ZAP-70 and CD38. If the CLL cells contain low amounts of these proteins, the leukemia tends to grow more slowly.

What are the other types of leukemia?

There are 4 main types of leukemia based on whether they are acute or chronic, and myeloid or lymphocytic:

- **Acute myeloid (or myelogenous) leukemia** (AML)
- **Chronic myeloid (or myelogenous) leukemia** (CML)
- **Acute lymphocytic (or lymphoblastic) leukemia** (ALL)
- Chronic lymphocytic leukemia (CLL)

In acute leukemias, the bone marrow cells cannot mature properly. Immature leukemia cells continue to reproduce and build up. Without treatment, most people with acute leukemia would live only a few months. Some types of acute leukemia respond well to treatment, and many patients can be cured. Other types of acute leukemia have a less favorable outlook.

Myeloid leukemias (also known as myelocytic, myelogenous, or non-lymphocytic leukemias) start in early forms of myeloid cells -- white blood cells (other than lymphocytes), red blood cells, or platelet-making cells (megakaryocytes).

Rarer forms of lymphocytic leukemia

The common form of CLL starts in B lymphocytes, but there are some rare types of leukemia that share some features with CLL.
Prolymphocytic leukemia (PLL): In this type of leukemia the cancer cells are similar to normal cells called prolymphocytes -- immature forms of B lymphocytes (B-PLL) or T lymphocytes (T-PLL). Both B-PLL and T-PLL tend to be more aggressive than the usual type of CLL. Most people will respond to some form of treatment, but over time they tend to relapse. PLL may develop in someone who already has CLL (in which case it tends to be more aggressive), but it can also occur in people who have never had CLL.

Large granular lymphocyte (LGL) leukemia: This is another rare form of chronic leukemia. The cancer cells are large and have features of either T lymphocytes or another type of lymphocyte called natural killer (NK) cells. Most LGL leukemias are slow-growing, but a small number are more aggressive. Drugs that suppress the immune system may be helpful, but aggressive cases are very hard to treat.

Hairy cell leukemia (HCL): This is another cancer of lymphocytes that tends to progress slowly. It accounts for about 2% of all leukemias. The cancer cells are a type of B lymphocyte but are different from those seen in CLL. There are also important differences in symptoms and treatment. This type of leukemia gets its name from the way the cells look under the microscope -- they have fine projections on their surface that make them look "hairy." Treatment for HCL can be very effective and is described in How is Chronic Lymphocytic Leukemia Treated?

The rest of this document focuses mainly on CLL in adults, with some limited information on hairy cell leukemia. For information on other types of leukemia in adults and children, please see our separate documents on these topics.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
different types of leukemia, it helps to know some basic facts about the blood and lymph systems.

Bone marrow

Bone marrow is the soft inner part of some bones such as the skull, shoulder blades, ribs, pelvis, and backbones. Bone marrow is made up of a small number of blood stem cells, more mature blood-forming cells, fat cells, and supporting tissues that help cells grow.

Inside the bone marrow, blood stem cells develop into new blood cells. During this process, the cells become either lymphocytes (a kind of white blood cell) or other blood-forming cells. These blood-forming cells can develop red blood cells, white blood cells (other than lymphocytes), or platelets.

Types of blood cells

Red blood cells carry oxygen from the lungs to all other tissues in the body, and take carbon dioxide back to the lungs to be removed. Having too few red blood cells in the body (anemia) can make you feel tired, weak, and short of breath because your body tissues are not getting enough oxygen.

Platelets are actually cell fragments made by a type of bone marrow cell called the megakaryocyte. Platelets are important in plugging up holes in blood vessels caused by cuts or bruises. Having too few platelets (thrombocytopenia) may cause you to bleed or bruise easily.

White blood cells help the body fight infections. Having too few white blood cells (neutropenia) lowers your immune system and can make you more likely to get an infection.

Types of white blood cells

Lymphocytes are mature, infection-fighting cells that develop from lymphoblasts, a type of blood stem cell in the bone marrow. Lymphocytes are the main cells that make up lymphoid tissue, a major part of the immune system. Lymphoid tissue is found in lymph nodes, the thymus gland, the spleen, the tonsils and adenoids, and is scattered throughout the digestive and respiratory systems and the bone marrow. There are 2 main types of lymphocytes:
B lymphocytes (B cells) protect the body from invading germs by developing (maturing) into plasma cells, which make proteins called antibodies. The antibodies attach to the germs (bacteria, viruses, and fungi), which helps other white blood cells called granulocytes to recognize and destroy them. B lymphocytes are the cells that most often develop into chronic lymphocytic leukemia (CLL) cells.

T lymphocytes (T cells) can recognize cells infected by viruses and directly destroy these cells. They also help regulate the immune system.

Granulocytes are mature, infection-fighting cells that develop from myeloblasts, a type of blood forming cell in the bone marrow. Granulocytes have granules that show up as spots under the microscope. These granules contain enzymes and other substances that can destroy germs, such as bacteria. The 3 types of granulocytes -- neutrophils, basophils, and eosinophils -- are distinguished under the microscope by the size and color of their granules.

Monocytes develop from blood-forming monoblasts in the bone marrow and are related to granulocytes. After circulating in the bloodstream for about a day, monocytes enter body tissues to become macrophages, which can destroy some germs by surrounding and digesting them. Macrophages also help lymphocytes recognize germs and start making antibodies to fight them.

**References**

See all references for Chronic Lymphocytic Leukemia
About 20,940 new cases of chronic lymphocytic leukemia (CLL)
About 4,510 deaths from CLL

CLL accounts for about one-quarter of the new cases of leukemia. The average person's lifetime risk of getting CLL is about \(\frac{1}{2}\) of 1\% (about 1 in 200). The risk is slightly higher in men than in women.

CLL mainly affects older adults. The average age at the time of diagnosis is around 71 years. It is rarely seen in people under age 40, and is extremely rare in children.

Visit the American Cancer Society’s Cancer Statistics Center for more key statistics.

References
See all references for Chronic Lymphocytic Leukemia


Last Medical Review: January 6, 2015 Last Revised: January 4, 2018

What's New in Chronic Lymphocytic Leukemia Research and Treatment?

Many studies of chronic lymphocytic leukemia (CLL) are being done in labs and in clinical trials around the world.

Genetics of chronic lymphocytic leukemia

Scientists are making great progress in understanding how changes in a person's DNA can cause normal bone marrow cells to develop into leukemia cells. Learning about changes in the genes (regions of the DNA) that often occur in CLL is providing insight into why these cells grow too quickly, live too long, and fail to develop into normal blood cells. Doctors are also learning how to use these changes to help them determine a person's outlook and whether they will need treatment.
New drugs for chronic lymphocytic leukemia

Dozens of new drugs are being tested for use against CLL. Many of these drugs are targeted at specific parts of cancer cells, while others are more like standard chemotherapy drugs.

Oblimersen (Genasense®) is a drug that has been studied for use in CLL. In studies, giving this drug along with chemo was more likely than chemo alone to cause the CLL to go into remission and stay there.

A number of new monoclonal antibodies (man-made versions of immune system proteins) are now being studied for use in CLL treatment. Lumiliximab is an antibody used to try to prompt the immune system to attack leukemia cells.

Other antibodies are attached to substances that can poison cancer cells, and are known as immunotoxins. They act as homing devices to deliver the toxins directly to the cancer cells. An immunotoxin known as BL22 has shown a great deal of promise in treating hairy cell leukemia (HCL) in clinical trials. A newer version of this drug, known as HA22 (CAT-8015) is now being tested for use against CLL.

Lenalidomide (Revlimid) is a drug approved to treat multiple myeloma and a certain kind of lymphoma. In studies, it has also shows promise in the treatment of CLL.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

2016 Copyright American Cancer Society
Chronic Lymphocytic Leukemia Causes, Risk Factors, and Prevention

Risk Factors

A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for chronic lymphocytic leukemia.

- What Are the Risk Factors for Chronic Lymphocytic Leukemia?
- Do We Know What Causes Chronic Lymphocytic Leukemia?

Prevention

There are very few known risk factors for chronic lymphocytic leukemia (CLL), and most of these cannot be avoided. Most CLL patients have no known risk factors, so there is no way to prevent these cancers.

What Are the Risk Factors for Chronic Lymphocytic Leukemia?

A risk factor is something that affects a person's chance of getting a disease like cancer. For example, exposing skin to strong sunlight is a risk factor for skin cancer. Smoking is a risk factor for a number of cancers.

But risk factors don't tell us everything. Having a risk factor, or even several risk factors, doesn’t mean that you will get the disease. And many people who get the disease may not have had any known risk factors. Even if a person has a risk factor and develops cancer, it is often very hard to know how much that risk factor may have contributed to the cancer.
There are very few known risk factors for chronic lymphocytic leukemia (CLL). These include:

- Exposure to certain chemicals
- Family history
- Gender
- Race/ethnicity

The risk of getting CLL does not seem to be affected by smoking, diet, or infections.

**Certain chemical exposures**

Some studies have linked exposure to Agent Orange, an herbicide used during the Vietnam War, to an increased risk of CLL. Some other studies have suggested that farming and long-term exposure to some pesticides may be linked to an increased risk of CLL, but more research in this area is needed.

**Family history**

First-degree relatives (parents, siblings, or children) of CLL patients have more than twice the risk for this cancer.

**Gender**

CLL is slightly more common in males than females, but the reasons for this are not known.

**Race/ethnicity**

CLL is more common in North America and Europe than in Asia. Asian people who live in the United States do not have a higher risk than those living in Asia. This is why experts think the differences in risk are related to genetics rather than environmental factors.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016
Do We Know What Causes Chronic Lymphocytic Leukemia?

The exact cause of most cases of chronic lymphocytic leukemia (CLL) is not known. But scientists have learned a great deal about the differences between normal lymphocytes and CLL cells in recent years.

Normal human cells grow and function based mainly on the information contained in each cell's chromosomes. Chromosomes are long molecules of DNA. DNA is the chemical that carries our genes -- the instructions for how our cells function. We look like our parents because they are the source of our DNA. But our genes affect more than the way we look.

Each time a cell prepares to divide into 2 new cells, it must make a new copy of the DNA in its chromosomes. This process is not perfect, and errors can occur that may affect genes within the DNA.

Some genes contain instructions for controlling when our cells grow and divide. Certain genes that promote cell growth and division are called oncogenes. Others that slow down cell division or cause cells to die at the right time are called tumor suppressor genes. Cancers can be caused by DNA mutations (changes) that turn on oncogenes or turn off tumor suppressor genes.

Each human cell contains 23 pairs of chromosomes. In most cases of CLL, a change can be found in at least one of these chromosomes. Most often this change is a deletion that is, loss of part of a chromosome. The loss of part of chromosome 13 is the most common deletion, but other chromosomes such as 11 and 17 can also be affected. Sometimes there is an extra chromosome 12 (trisomy 12). Other, less common abnormalities may also be found. Scientists know these chromosome changes are important in CLL, but it's not yet clear which genes they involve or exactly how they lead to leukemia.

We do know that normal B lymphocytes are part of the immune system. They are programmed to grow and divide when they come into contact with a foreign substance called an antigen. (Scientists call substances foreign if they don't normally occur in a
person’s body and can be recognized by their immune system. Germs contain foreign antigens. So do blood cells from someone else with a different blood type.) Scientists think that CLL begins when B lymphocytes continue to divide without restraint after they have reacted to an antigen. But why this happens is not yet known.

Sometimes people inherit DNA mutations from a parent that greatly increase their risk of getting certain types of cancer. But inherited mutations rarely cause CLL. DNA changes related to CLL usually occur during the person’s lifetime, rather than having been inherited before birth.

- **References**

[See all references for Chronic Lymphocytic Leukemia](#)

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our [Content Usage Policy](#).

### Can Chronic Lymphocytic Leukemia Be Prevented?

Many types of cancer can be prevented by lifestyle changes to avoid certain risk factors, but there are very few [known risk factors for chronic lymphocytic leukemia (CLL)](#), and most of these cannot be avoided. Most CLL patients have no known risk factors, so there is no way to prevent these cancers.

2016 Copyright American Cancer Society
Chronic Lymphocytic Leukemia Early Detection, Diagnosis, and Staging

Detection and Diagnosis

Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that is not always the case.

- Can Chronic Lymphocytic Leukemia Be Found Early?
- Signs and Symptoms of Chronic Lymphocytic Leukemia
- How Is Chronic Lymphocytic Leukemia Diagnosed?

Stages and Outlook (Prognosis)

After a cancer diagnosis, staging provides important information about the extent of cancer in the body and anticipated response to treatment.

- How Is Chronic Lymphocytic Leukemia Staged?

Questions to Ask About CLL

Here are some questions you can ask your cancer care team to help you better understand your CML diagnosis and treatment options.

- What Should You Ask Your Doctor About Chronic Lymphocytic Leukemia?

Can Chronic Lymphocytic Leukemia Be Found Early?

For certain cancers, the American Cancer Society recommends screening tests in
people without any symptoms, because they are easier to treat if found early. But for chronic lymphocytic leukemia (CLL), no screening tests are routinely recommended at this time.

Sometimes, CLL is found when routine blood tests are done for other reasons. For instance, a person's white blood cell count may be very high, even though he or she doesn't have any symptoms.

If you notice any symptoms that could be caused by CLL, report them to your doctor right away so the cause can be found and treated, if needed.

- References
See all references for Chronic Lymphocytic Leukemia

Signs and Symptoms of Chronic Lymphocytic Leukemia

Many people with CLL do not have any symptoms when it is diagnosed. The leukemia is often found when their doctor orders blood tests for some unrelated health problem or during a routine checkup and they are found to have a high number of lymphocytes.

Even when people with CLL have symptoms, they are often vague and can be symptoms of other things. Symptoms can include the following:

- Weakness
- Feeling tired
- Weight loss
- Fever
- Night sweats
- Enlarged lymph nodes (often felt as lumps under the skin)
- Pain or a sense of "fullness" in the belly (this can make someone feel full after only
a small meal), which is caused by an enlarged spleen and/or liver

Many of the signs and symptoms of advanced CLL occur because the leukemia cells replace the bone marrow’s normal blood-making cells. As a result, people do not make enough red blood cells, properly functioning white blood cells, and blood platelets.

- **Anemia** is a shortage of red blood cells. It can cause tiredness, weakness, and shortness of breath.
- A shortage of normal white blood cells (*leukopenia*) increases the risk of *infections*. You might hear the term *neutropenia*, which refers specifically to low levels of neutrophils (a type of granulocyte needed to fight bacterial infections). People with CLL may have very high white blood cell counts because of excess numbers of lymphocytes (*lymphocytosis*), but the leukemia cells do not protect against infection the way normal white blood cells do.
- A shortage of blood platelets (*thrombocytopenia*) can lead to excess bruising, bleeding, frequent or severe nosebleeds, and bleeding gums.

People with CLL have a higher risk of infections. This is mainly because their immune systems are not working as well as they should. CLL is a cancer of B lymphocytes, which normally make antibodies that help fight infection. Because of the CLL, these antibody-making cells don't work as they should, so they can't fight infections well. Infections may range from simple things like frequent colds or cold sores to pneumonia and other serious infections.

CLL may also affect the immune system in other ways. In some people with CLL, the immune system cells make abnormal antibodies that attack normal blood cells. This is known as *autoimmunity*. It can lead to low blood counts. If the antibodies attack red blood cells, it is known as *autoimmune hemolytic anemia*. Less often, the antibodies attack platelets and the cells that make them, leading to low platelet counts. Rarely, the antibodies attack white blood cells, leading to leukopenia (low white blood cell counts).

These symptoms and signs may be caused by CLL, but they can also be caused by other conditions. Still, if you have any of these problems, it's important to see your doctor right away so the cause can be found and treated, if needed.

- **References**
  See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016
How Is Chronic Lymphocytic Leukemia Diagnosed?

Certain signs and symptoms might suggest that a person has chronic lymphocytic leukemia (CLL), but tests are needed to confirm the diagnosis.

Medical history and physical exam

If you have any signs or symptoms that suggest you might have leukemia, your doctor will want to take a complete medical history to check for symptoms and possible risk factors. You will also be asked about your general health.

A physical exam provides information about your general health, possible signs of leukemia, and other health problems. During the physical exam, your doctor will pay close attention to your lymph nodes and other areas that might be affected.

Tests used to diagnose and classify leukemia

If symptoms and/or the results of the physical exam suggest you could have leukemia, the doctor will need to check samples of blood and bone marrow to be certain of this diagnosis. Other tissue and cell samples may also be taken to help guide treatment.

Blood tests

Blood samples for tests for CLL generally are taken from a vein in the arm.

Complete blood count and blood cell exam (peripheral blood smear)

The complete blood count (CBC) is a test that measures the different cells in the blood, such as the red blood cells, the white blood cells, and the platelets. This test is often done along with a differential (or diff) which looks at the numbers of the different types of white blood cells. These tests are often the first ones done on patients with a suspected blood problem.
People with CLL have too many lymphocytes (called \textit{lymphocytosis}). Having more than 10,000 lymphocytes/mm\(^3\) (per cubic millimeter) of blood strongly suggests that CLL is present, but other tests are needed to know for certain. You might also have too few red blood cells and blood platelets as well.

For the peripheral blood smear, a sample of blood is looked at under the microscope. If you have CLL, the blood smear could show many abnormal looking lymphocytes called \textit{smudge cells}.

\textbf{Flow cytometry}

This test is important in diagnosing CLL. It uses a machine that looks for certain substances on or in cells that help identify what types of cells they are (markers).

This test can be used to see if the lymphocytes in a sample of blood contain CLL cells. It can also be used to look for CLL cells in bone marrow or other fluids. CLL cells can have many of the same markers as normal B-cells. However, they also have a marker called \textit{CD5} that is normally found on T-cells, but not on normal B cells. For someone to have CLL, there must be at least 5,000 of these cells (per mm\(^3\)) in the blood.

Flow cytometry can also be used to test for substances called \textit{ZAP-70} and \textit{CD38} on the cells. Studies suggest that CLL with fewer cells that have these substances seem to have a better outlook. This is discussed in more detail in \textit{How Is Chronic Lymphocytic Leukemia Staged?}

\textbf{Other blood tests}

Other tests may be done to measure the amount of certain chemicals in the blood, but they are not used to diagnose leukemia. In patients already known to have CLL, these tests help detect liver or kidney problems caused by the spread of leukemia cells or due to the side effects of certain chemotherapy (chemo) drugs. These tests also help determine if treatment is needed to correct low or high blood levels of certain minerals. If treatment with the drug rituximab (Rituxan\textsuperscript{®}) is planned, the doctor may order blood tests to check for previous hepatitis infection (this is discussed further in \textit{Monoclonal Antibodies for Chronic Lymphocytic Leukemia}).

Blood immunoglobulin (antibody) levels may be tested to check if you enough antibodies to fight infections, especially if you have recently had many infections. Another blood protein called \textit{beta-2-microglobulin} may be measured. High levels of this protein generally indicate a more advanced CLL.

\textbf{Bone marrow tests}
Blood tests are often enough to diagnose CLL, but testing the bone marrow is helpful to tell how advanced it is. Bone marrow tests are often done before starting treatment for that reason. They might also be repeated during or after treatment to see if the treatment is effective.

**Bone marrow aspiration and biopsy**

Bone marrow aspiration and biopsy are done to get bone marrow samples for testing. They are usually done together, as part of the same procedure. The samples are usually taken from the back of the pelvic (hip) bone, but sometimes they may be taken from other bones.

For a bone marrow *aspiration*, you lie on a table (either on your side or on your belly). After cleaning the skin over the hip, the doctor numbs the area and the surface of the bone with local anesthetic, which may cause a brief stinging or burning sensation. A thin, hollow needle is then inserted into the bone and a syringe is used to suck out a small amount (about 1 teaspoon) of liquid bone marrow. Even with the anesthetic, most people still have some brief pain when the marrow is removed.

A bone marrow *biopsy* is usually done just after the aspiration. A small piece of bone and marrow (about 1/16 inch in diameter and 1/2 inch long) is removed with a slightly larger needle that is twisted as it is pushed down into the bone. With the local anesthetic, this most often causes a feeling of pressure or tugging, but is not often painful. Once the biopsy is done, pressure will be applied to the site to help prevent bleeding.

**Routine microscopic exams**

The bone marrow samples are looked at under a microscope by a pathologist (a doctor specializing in lab tests) and may be reviewed by the patient's hematologist/oncologist (a doctor specializing in blood diseases and cancer).

The doctors will look at the size, shape, and other traits of the white blood cells in the samples to classify them into specific types.

An important factor is if the cells look mature (like normal blood cells that can fight infections). Chronic lymphocytic leukemia cells usually appear mature, while cells of acute leukemias look immature.

A key feature of a bone marrow sample is its cellularity. Normal bone marrow has a certain number of blood-forming cells and fat cells. Marrow with too many blood-forming cells is said to be *hypercellular*. This is often seen in bone marrow of CLL patients.
Doctors also look to see how much of the normal cells in the bone marrow have been replaced by CLL cells.

The pattern of spread of CLL cells in the bone marrow is also important. A pattern where the cells are in small groups (nodular or interstitial pattern) often indicates a better outlook than if the cells are scattered throughout the marrow (a diffuse pattern).

Stains and/or antibody tests such as cytochemistry, immunocytochemistry, immunohistochemistry, and flow cytometry may be used on the bone marrow samples to diagnose CLL.

**Gene tests**

**Cytogenetics:** For this test, bone marrow cells (or sometimes cells from the blood or other tissues) are grown in the lab, and the chromosomes are examined under a microscope. Because it takes time for the cells to start dividing, this test usually takes weeks to complete. Normal human cells contain 23 pairs of chromosomes, but some cases of CLL have chromosome changes that can be seen under the microscope.

In some cases of CLL, part of a chromosome may be missing. This is called a deletion. The most common deletions occur in parts of chromosomes 13, 11, or 17. Deletion of part of chromosome 17 (often written as del[17]) is linked to a poor outlook. Other, less common chromosome changes include an extra copy of chromosome 12 (trisomy 12) or a translocation (swapping of DNA) between chromosomes 11 and 14 (written as t[11;14]).

This information may be helpful to determine a patient’s prognosis (outlook), but it needs to be looked at along with other factors, such as the stage of CLL. The loss of part of chromosome 13 is usually linked with a slower-growing disease and a better outlook, while defects in chromosomes 11 or 17 often indicate a poorer outlook. Trisomy 12 does not seem to have much of an effect on prognosis.

**Fluorescent in situ hybridization (FISH):** This is a type of chromosome test that can be used to look at the cells’ chromosomes and DNA without having to grow the cells in the lab. It uses special fluorescent dyes that only attach to specific parts of particular chromosomes. FISH is used to look for certain genes or chromosome changes (not just any change). It can be used on regular blood or bone marrow samples. Because the cells don’t have to grow in the lab first, it can usually provide results more quickly than cytogenetics, often within a couple of days.

**Molecular tests:** Immunoglobulins, the antibodies that help your body fight infections,
are made up of light chains and heavy chains. Whether the gene for the immunoglobulin heavy chain variable region (IGHV or IgV_H) has changed (mutated) can help your doctor know how aggressive your CLL is. That gene is looked at in a test called cDNA sequencing.

**Lymph node biopsy**

In a lymph node biopsy, all or part of a lymph node is removed so that it can be examined under the microscope to see if it contains cancer cells. Although this is often done to diagnose lymphomas, it is only rarely needed in CLL. It may be used if a lymph node has grown very large and the doctor wants to know if the leukemia has changed (transformed) into a more aggressive lymphoma.

In an *excisional lymph node biopsy*, an entire lymph node is removed through a cut in the skin. If the node is near the skin surface, this is a simple operation that can be done with local anesthesia, but if the node is inside the chest or abdomen, general anesthesia (where the patient is asleep) is used. If the lymph node is very large, only part of it may be removed. This is called an *incisional biopsy*.

**Lumbar puncture (or spinal tap)**

This procedure is used to take samples of the fluid that surrounds the brain and spinal cord (the cerebrospinal fluid or CSF) for testing. This is not a routine test for people with CLL. It is only done if the doctor suspects leukemia cells may have spread to the area around the brain or spinal cord (which is rare), or if there might be an infection in those areas.

For this test, the doctor first numbs an area in the lower part of the back over the spine. A small, hollow needle is then placed between the bones of the spine and into the space around the spinal cord to collect some of the fluid.

**Imaging tests**

Imaging tests use x-rays, sound waves, or magnetic fields to create pictures of the inside of the body. Imaging tests are not done to diagnose the leukemia, but they may be done for other reasons, including to help find a suspicious area that might be cancerous, to learn how far a cancer may have spread, or to help determine if treatment has been effective.

**Computed tomography (CT) scan**
The **CT scan** can help tell if any lymph nodes or organs in your body are enlarged. It isn't usually needed to diagnose CLL, but it may be done if your doctor suspects the leukemia is growing in an organ, like your spleen.

Sometimes a CT scan is combined with a PET scan in a test known as a PET/CT scan. For a PET scan, glucose (a form of sugar) containing a radioactive atom is injected into the blood. Because cancer cells grow rapidly, they absorb large amounts of the radioactive sugar. A special camera can then create a picture of the areas of radioactivity in the body. The PET/CT scan combines both tests in one machine. This test allows the doctor to compare areas of higher radioactivity on the PET scan with the more detailed appearance of that area on the CT.

**Magnetic resonance imaging (MRI) scan**

**MRI scans** are most useful in looking the brain and spinal cord, but they are not often needed in people with CLL.

MRI scans take longer than CT scans—often up to an hour. You might have to lie inside a narrow tube, which is confining and can be distressing to some people. Newer, more open MRI machines may be another option. The MRI machine makes loud buzzing and clicking noises that you may find disturbing. Some places provide headphones or earplugs to help block this noise out.

**Ultrasound**

**Ultrasound** can be used to look at lymph nodes near the surface of the body or to look for enlarged organs (like the liver and spleen) inside your abdomen.

This is an easy test to have, and it uses no radiation. For most ultrasound exams, you simply lie on a table, and a technician moves the transducer over the part of your body being looked at.
How Is Chronic Lymphocytic Leukemia Staged?

For most cancers, staging is the process of finding out how far the cancer has spread. Stages are often useful because they can help guide treatment and determine a person's prognosis (outlook). Most types of cancer are staged based on the size of the tumor and how far the cancer has spread.

Chronic lymphocytic leukemia (CLL), on the other hand, does not usually form tumor masses. It generally is present in the bone marrow and blood, and, in many cases, it has spread to other organs such as the spleen, liver, and lymph nodes by the time it is found. Therefore, the outlook for a person with CLL depends on other information, such as the lab test results and the results of imaging tests.

Staging for chronic lymphocytic leukemia

A staging system is a standardized way for the cancer care team to summarize information about how far a cancer has spread. There are 2 different systems for staging CLL:

- **Rai system**: This is used more often in the United States.
- **Binet system**: This is used more widely in Europe.

Rai staging system

The Rai system was originally devised in 1968. At that time, all that was needed to diagnose CLL was lymphocytosis - a high number of lymphocytes in the blood and bone marrow that didn't have any other cause (like infection). This was originally defined as over 15,000 lymphocytes/mm$^3$ of blood and at least 40% of the bone marrow being made up of lymphocytes.

Now, for a diagnosis of CLL, the patient must have at least 5,000/mm$^3$ of *monoclonal* lymphocytes (sometimes called a monoclonal lymphocytosis), but the overall lymphocyte count does not have to be high. Monoclonal means that the cells all came from the same cell, which can lead to them having the same chemical pattern on special testing.

For the purposes of this staging, you can substitute a diagnosis of CLL (such as with a
monoclonal lymphocytosis) for lymphocytosis.

This system divides CLL into 5 stages:

- **Rai stage 0**: Lymphocytosis and no enlargement of the lymph nodes, spleen, or liver, and with near normal red blood cell and platelet counts.
- **Rai stage I**: Lymphocytosis plus enlarged lymph nodes. The spleen and liver are not enlarged and the red blood cell and platelet counts are near normal.
- **Rai stage II**: Lymphocytosis plus an enlarged spleen (and possibly an enlarged liver), with or without enlarged lymph nodes. The red blood cell and platelet counts are near normal.
- **Rai stage III**: Lymphocytosis plus anemia (too few red blood cells), with or without enlarged lymph nodes, spleen, or liver. Platelet counts are near normal.
- **Rai stage IV**: Lymphocytosis plus thrombocytopenia (too few blood platelets), with or without anemia, enlarged lymph nodes, spleen, or liver.

Doctors separate the Rai stages into low-, intermediate-, and high-risk groups when determining treatment options.

- Stage 0 is considered low risk.
- Stages I and II are considered intermediate risk.
- Stages III and IV are considered high risk.

These risk groups are used later in How Is Chronic Lymphocytic Leukemia Treated?

**Binet staging system**

In the Binet staging system, CLL is classified by the number of affected lymphoid tissue groups (neck lymph nodes, groin lymph nodes, underarm lymph nodes, spleen, and liver) and by whether or not the patient has anemia (too few red blood cells) or thrombocytopenia (too few blood platelets).

- **Binet stage A**: Fewer than 3 areas of lymphoid tissue are enlarged, with no anemia or thrombocytopenia.
- **Binet stage B**: 3 or more areas of lymphoid tissue are enlarged, with no anemia or thrombocytopenia.
- **Binet stage C**: Anemia and/or thrombocytopenia are present.

Both of these staging systems are helpful and have been in use for many years.

Other factors can also help predict a person's outlook. The factors described below are not part of formal staging systems (at least at this time), but they can also provide
Prognostic factors for chronic lymphocytic leukemia

Along with the stage, there are other factors that help predict a person's outlook. These factors are sometimes taken into account when looking at possible treatment options. Factors that tend to be linked with shorter survival time are called adverse prognostic factors. Those that predict longer survival are favorable prognostic factors.

Adverse prognostic factors

- Diffuse pattern of bone marrow involvement (more widespread replacement of normal marrow by leukemia)
- Advanced age
- Male gender
- Deletions of parts of chromosomes 17 or 11
- High blood levels of certain substances, such as beta-2-microglobulin
- Lymphocyte doubling time (the time it takes for the lymphocyte count to double) of less than 6 months
- Increased fraction of prolymphocytes (an early form of the lymphocyte) in the blood
- High proportion of CLL cells containing ZAP-70 (more than 20%) or CD38 (more than 30%)
- CLL cells with unchanged (not mutated) gene for the immunoglobulin heavy chain variable region (IGHV)

Favorable prognostic factors

- Non-diffuse (nodular or interstitial) pattern of bone marrow involvement
- Deletion of part of chromosome 13 (with no other chromosome abnormalities)
- Low proportion of CLL cells containing ZAP-70 (20% or less) or CD38 (30% or less)
- CLL cells with a mutated gene for IGHV

Certain prognostic factors such as the presence or absence of ZAP-70, CD38, and a mutated gene for IGHV help divide cases of CLL into 2 groups, slow growing and fast growing. People with the slower growing kind of CLL tend to live longer and may be able to delay treatment longer as well.

Staging for hairy cell leukemia
There is no generally accepted staging system for hairy cell leukemia.

**Monoclonal B-lymphocytosis**

Some people have monoclonal lymphocytes in their blood, but not enough to make the diagnosis of CLL. If someone has less than 5,000 monoclonal lymphocytes (per mm$^3$), normal counts of red blood cells and platelets, and no enlarged lymph nodes (or enlarged spleen), they have a condition called monoclonal B-lymphocytosis (MBL). MBL doesn’t need to be treated, but about one patient of every 100 with this condition will go on to need treatment for CLL.

**Small lymphocytic lymphoma**

The cancer cells of small lymphocytic lymphoma (SLL) and CLL look the same under the microscope and have the same marker proteins on the surface of the cells. Whether someone is diagnosed with SLL or CLL depends largely on the number of lymphocytes in the blood. To be diagnosed with CLL, there must at least 5,000 monoclonal lymphocytes (per mm$^3$) in the blood. For it to be called SLL, the patient must have enlarged lymph nodes or an enlarged spleen with fewer than 5,000 lymphocytes (per mm$^3$) in the blood. Still, since SLL and CLL can be treated the same, the difference between them is not really important.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

**What Should You Ask Your Doctor About Chronic Lymphocytic Leukemia?**

As you cope with cancer and cancer treatment, you need to have honest, open discussions with your doctor. You should feel comfortable asking any question, no
matter how small it might seem. Here are some questions you might want to ask. Nurses, social workers, and other members of the treatment team may also be able to answer many of your questions.

- What is the stage (risk group) of the leukemia, and what does that mean for me?
- Will I need to have other tests before we can decide on treatment?
- How much experience do you have treating this type of cancer?
- Should I get a second opinion?
- Should I be treated at this time? Why or why not?
- What are my treatment choices?
- What do you recommend, and why?
- What are the risks and side effects with the treatments that you recommend?
- What should I do to be ready for treatment?
- How long will treatment last? What will it be like? Where will it be done?
- How will treatment affect my daily activities?
- What is the outlook for my survival?
- What will we do if the treatment doesn't work or if the leukemia recurs?
- What type of follow-up will I need after treatment?

Be sure to write down any questions that occur to you that are not on this list. For instance, you might want information about recovery times so that you can plan your work schedule. Or you may want to ask about clinical trials for which you may qualify.

Taking another person and/or a tape recorder to your doctor visit can be helpful. Collecting copies of your medical records, pathology reports, and radiology reports may be useful in case you wish to seek a second opinion at a later time.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

2016 Copyright American Cancer Society
For additional assistance please contact your American Cancer Society
1-800-227-2345 or www.cancer.org
Treating Chronic Lymphocytic Leukemia

Making treatment decisions

After the leukemia is found and staged, your cancer care team will discuss your treatment options with you. Because chronic lymphocytic leukemia often grows slowly, not everyone needs to be treated right away. When treatment is needed, the main treatments used are:

- Chemotherapy
- Monoclonal antibodies
- Targeted therapy
- Supportive care
- Stem cell transplant

Less often, leukapheresis, surgery, or radiation therapy may also be used.

It is important to take time and think about your possible choices. In choosing a treatment plan, the stage of the leukemia and other prognostic factors (see How is Chronic Lymphocytic Leukemia Staged?) are important. Other factors to consider include whether or not you are having symptoms, your age and overall health, and the likely benefits and side effects of treatment. See Typical Treatment of Chronic Lymphocytic Leukemia or Treating Hairy Cell Leukemia to learn about common treatment plans.

In considering your treatment options it is often a good idea to seek a second opinion, if possible. This could give you more information and help you feel more confident about the treatment plan you have chosen.

Thinking about taking part in a clinical trial
Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-of-the-art cancer treatment. In some cases they may be the only way to get access to newer treatments. They are also the best way for doctors to learn better methods to treat cancer. Still, they are not right for everyone.

If you would like to learn more about clinical trials that might be right for you, start by asking your doctor if your clinic or hospital conducts clinical trials. See Clinical Trials to learn more.

**Considering complementary and alternative methods**

You may hear about alternative or complementary methods that your doctor hasn’t mentioned to treat your cancer or relieve symptoms. These methods can include vitamins, herbs, and special diets, or other methods such as acupuncture or massage, to name a few.

Complementary methods refer to treatments that are used along with your regular medical care. Alternative treatments are used instead of a doctor’s medical treatment. Although some of these methods might be helpful in relieving symptoms or helping you feel better, many have not been proven to work. Some might even be dangerous.

Be sure to talk to your cancer care team about any method you are thinking about using. They can help you learn what is known (or not known) about the method, which can help you make an informed decision. See the Complementary and Alternative Medicine section to learn more.

**Help getting through cancer treatment**

Your cancer care team will be your first source of information and support, but there are other resources for help when you need it. Hospital- or clinic-based support services are an important part of your care. These might include nursing or social work services, financial aid, nutritional advice, rehab, or spiritual help.

The American Cancer Society also has programs and services – including rides to treatment, lodging, support groups, and more – to help you get through treatment. Call our National Cancer Information Center at 1-800-227-2345 and speak with one of our trained specialists.

*The treatment information given here is not official policy of the American Cancer*
Chemotherapy for Chronic Lymphocytic Leukemia

Chemotherapy (chemo) uses anti-cancer drugs that are taken by mouth or injected into a vein or into a muscle to destroy or control cancer cells. When given this way, these drugs enter the bloodstream and reach all areas of the body, so chemotherapy is useful for cancers such as leukemia that tend to spread throughout the body.

When treating certain types of leukemia, chemo may also be injected into the cerebrospinal fluid. Chemo given into the CSF is often the best way to treat leukemia in the area around the brain and spinal cord. This type of chemo, called intrathecal chemotherapy, is rarely needed to treat chronic lymphocytic leukemia (CLL).

Doctors give chemo in cycles, with each period of treatment followed by a rest period to allow the body time to recover. Chemo cycles generally last about 3 to 4 weeks. Chemo is often not recommended for patients in poor health, but advanced age by itself is not a barrier to getting chemo.

The major types of chemo drugs used to treat CLL include:

**Purine analogs** include fludarabine (Fludara®), pentostatin (Nipent®), and cladribine (2-CdA, Leustatin®). Fludarabine is often one of the first drugs used against CLL. These drugs can have major side effects, including an increased risk of infection.

**Alkylating agents**, which include chlorambucil (Leukeran®) and cyclophosphamide (Cytoxan®), have been around much longer. They are often used along with a purine analog, with other chemo drugs, with a corticosteroid, or with the monoclonal antibody rituximab (Rituxan®).

A newer drug called bendamustine (Treanda®) is an alkylating agent that has some properties of a purine analog.

**Corticosteroids** such as prednisone, methylprednisolone, and dexamethasone.
Other drugs sometimes used for CLL include doxorubicin (Adriamycin®), methotrexate, oxaliplatin, vincristine (Oncovin®), etoposide (VP-16), and cytarabine (ara-C).

Possible side effects

Chemotherapy drugs work by attacking cells that are dividing quickly, which is why they work against cancer cells. But other cells in the body, such as those in the bone marrow, the lining of the mouth and intestines, and the hair follicles, also divide quickly. These cells are also likely to be affected by chemotherapy, which can lead to side effects.

The side effects of chemotherapy depend on the type and dose of drugs given and the length of time they are taken. Common side effects include:

- Hair loss
- Mouth sores
- Loss of appetite
- Nausea and vomiting
- Low blood counts

Chemo can affect bone marrow, leading to low blood cell counts. This can cause:

- Increased risk of infections (due to low white blood cell counts)
- Easy bruising or bleeding (due to low blood platelets)
- Fatigue (due to low red blood cells)

These side effects are usually short-term and go away once treatment is finished. There are often ways to lessen these side effects. For example, there are drugs to help prevent or reduce nausea and vomiting. Be sure to ask your doctor or nurse about medicines to help reduce side effects, and let him or her know when you do have side effects so they can be managed effectively.

Drugs known as growth factors (such as G-CSF/Neupogen®, pegfilgrastim/Neulasta®, and GM-CSF/sargramostim) are sometimes given to increase the white blood cell counts and thus reduce the chance of infection.

For information on infections and how to avoid them, see Infections in People With Cancer.

Tumor lysis syndrome is another possible side effect of chemo. It is most common in patients who had large numbers of leukemia cells in the body before treatment and occurs most often with the first cycle of chemo. When the cells are killed, they break
open and release their contents into the bloodstream. This can overwhelm the kidneys, which cannot get rid of all of these substances at once. This can lead to build up of excess amounts of certain minerals in the blood and even kidney failure. The excess minerals can lead to problems with the heart and nervous system. Doctors work to prevent these problems by giving the patient extra fluids and certain drugs, such as sodium bicarbonate, allopurinol, and rasburicase.

For more general information about chemotherapy, see the Chemotherapy section of our website.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

Monoclonal Antibodies for Chronic Lymphocytic Leukemia

Monoclonal antibodies are man-made versions of immune system proteins (antibodies) that are designed to attach to a specific target (in this case, proteins on the surface of cancer cells). These drugs can help your immune system react and destroy the cancer cells. Some monoclonal antibodies also fight cancer in other ways.

The monoclonal antibodies used to treat chronic lymphocytic leukemia (CLL) can be divided into groups based on which protein they target.

Targeting CD20

A number of monoclonal antibody drugs used to treat CLL target the CD20 antigen, a protein found on the surface of B lymphocytes. These include:

- Rituximab (Rituxan)
- Obinutuzumab (Gazyva®)
- **Ofatumumab (Arzerra®)**

Rituximab is used mainly to treat certain kinds of non-Hodgkin lymphoma, but it has also become one of the main treatments for chronic lymphocytic leukemia (CLL). It is most often used along with chemotherapy, either as part of the initial treatment or as part of a second-line regimen, but it may also be used by itself.

Obinutuzumab can be used along with the chemo drug chlorambucil as a part of the initial treatment for CLL.

Ofatumumab is used mainly if CLL is no longer responding to other treatments such as chemotherapy or other monoclonal antibodies such as alemtuzumab (discussed below).

These drugs are given by infusion into a vein (IV), which can take up to several hours depending on the drug. They all can cause side effects during the infusion (while the drug is being given) or several hours afterwards. These can be mild, such as itching/chills, fever, nausea, rashes, fatigue, and headaches. More serious side effects can also occur during the infusion, including chest pain, heart racing, swelling of the face and tongue, cough, trouble breathing, feeling dizzy or light headed, and feeling faint. Because of these kinds of reactions, drugs to help prevent them are given before each infusion.

There is also a form of rituximab that is given as a shot under the skin. It can take 5-7 minutes to inject the drug, but this is much shorter than the time it normally takes to give the drug by vein. It is approved for use in patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Possible side effects include local skin reactions, like redness, where the drug is injected, infections, low white blood cell counts, nausea, fatigue, and constipation.

All of these drugs can cause hepatitis B infections that were dormant (inactive) to become active again, which can lead to severe liver problems or even death. For that reason, your doctor may check your blood for signs of an old hepatitis infection before starting this drug. If your blood shows signs of an old hepatitis B infection, the doctor will check your blood during treatment to see if the virus becomes active again. If it does, the drug will need to be stopped.

These drugs may also increase a person's risk of certain serious infections for many months after the drug is stopped. For example, rituximab has been linked to a rare brain disease known as progressive multifocal leukoencephalopathy (PML) that is caused by a virus. It can lead to headache, high blood pressure, seizures, confusion, loss of vision, and even death.

Other side effects can occur depending on which drug is given. Ask your doctor what
you can expect.

In rare cases of patients with very high white blood cell counts, some of these drugs may cause a condition called *tumor lysis syndrome* (this was discussed in detail in the chemotherapy section). This happens when the drug kills the cancer cells so quickly that the body has trouble getting rid of the breakdown products of the dead cells. It generally only occurs during the first course of treatment.

**Targeting CD52**

Alemtuzumab (Campath®) is a monoclonal antibody that targets the CD52 antigen, which is found on the surface of CLL cells and many T lymphocytes. It is used mainly if CLL is no longer responding to standard chemotherapy treatments, but it can be used earlier in the disease. It may be especially useful in cases of CLL with a chromosome 17 deletion, which are often resistant to standard treatments, but it doesn’t seem to work as well in people whose lymph nodes are enlarged (2 inches across or larger).

Alemtuzumab is given by injection into a vein (intravenous or IV), usually several times a week. In studies, it has also been given as an injection under the skin (subcutaneously), but giving it this way is not approved by the Food and Drug Administration. The most common side effects are fever, chills, nausea, and rashes during the injection, but these effects seem to be less of a problem when it is given under the skin. It can also cause very low white blood cell counts, which increases the risk for severe bacterial and viral infections. Antibiotic and antiviral medicines are given to help protect against some of these infections, but severe and even life-threatening infections can still occur. It may also cause low red blood cell and platelet counts.

You can learn more about monoclonal antibodies in [Immunotherapy](https://www.cancer.org/cancer/chroniclymphocyticleukemia--cll/treatment-and-side-effects/treatment-options/targeted-therapy.html).

- References
  
  See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016
Lymphocytic Leukemia

Researchers are developing newer drugs that specifically target the changes inside cells that cause them to become cancerous. Unlike standard chemotherapy drugs, which work by attacking rapidly growing cells in general (including cancer cells), these drugs attack one or more specific targets on or in cancer cells.

**Ibrutinib (Imbruvica)** is a targeted drug that can be used to treat chronic lymphocytic leukemia (CLL). It blocks the activity of a protein called a kinase that tells the leukemia cells to divide and helps them survive. This drug has been shown to help when CLL is hard to treat, for example, if there are chromosome 17 deletions or if CLL has come back after other treatments.

This drug is taken in pill form. Side effects tend to be mild, but can include diarrhea, nausea, constipation, fatigue, shortness of breath, swelling of the feet and hands, body aches, and rash. Low blood counts, including low red blood cell counts (anemia), low levels of certain white blood cells (neutropenia), and platelet counts (thrombocytopenia), are also common side effects. Some people treated with this drug get infections which can be serious. Other side effects can also be seen, so ask your doctor what you can expect.

**Idelalisib (Zydelig)** is another targeted drug for CLL. It blocks a kinase protein called PI3K. This drug has been shown to help treat CLL after other treatments have been tried. It is taken as a pill twice a day.

Common side effects include diarrhea, fever, fatigue, nausea, cough, pneumonia, belly pain, chills, and rash. Low blood counts, including low red blood cell counts (anemia), low levels of certain white blood cells (neutropenia), and platelet counts (thrombocytopenia), are also common. Less often, more serious side effects can occur, such as liver damage, severe diarrhea, lung inflammation (pneumonitis), serious allergic reactions, severe skin problems, and holes (perforations) in the intestines.

**Venetoclax (Venclexta)** is a drug that targets BCL-2, a protein in CLL cells that helps them survive longer than they should. This drug is used in patients whose CLL cells have a chromosome 17p deletion, typically after at least one other treatment has been tried. It is taken as a pill once a day.

Side effects can include low levels of certain white blood cells (neutropenia), low red blood cell counts (anemia), diarrhea, nausea, respiratory infections (such as colds), low platelet counts (thrombocytopenia), and feeling tired. Less common but more serious side effects can include pneumonia and other serious infections, and tumor lysis.
syndrome (in which many leukemia cells break open and spill their contents into the body).

For more information about targeted therapy, see Targeted Therapy.

- References
See all references for Chronic Lymphocytic Leukemia

Surgery for Chronic Lymphocytic Leukemia

Surgery has a very limited role in treating chronic lymphocytic leukemia (CLL). Because CLL cells tend to spread widely throughout the bone marrow and to many organs, surgery cannot cure this type of cancer. It is rarely needed even to diagnose CLL, which can often be done with a blood sample. However, sometimes minor surgery is needed to remove a lymph node to aid in diagnosing or staging the cancer.

Splenectomy

In rare cases, the spleen may be removed (splenectomy). This is not expected to cure the leukemia, but it can help improve some of the symptoms. Sometimes CLL can make the spleen grow so large that it presses on nearby organs and causes symptoms. If radiation or chemotherapy does not help shrink the spleen and reduce symptoms, splenectomy may be an option.

Splenectomy may also improve blood cell counts and lower the need for blood product transfusions. One of the spleen’s normal functions is to remove worn-out blood cells from the bloodstream. If the spleen becomes too large, it may become too active in removing blood cells, leading to a shortage of red blood cells or platelets. When this happens, taking out the spleen can help improve blood counts. This is done much more often for patients with hairy cell leukemia than for those with regular CLL.
Most people have no problem living without a spleen, but the risk for certain bacterial infections is increased. Doctors recommend certain vaccines for people before their spleen is removed. If your spleen has been removed, be sure to report any symptoms of infections promptly to your health care team.

- References

See all references for Chronic Lymphocytic Leukemia

Radiation Therapy for Chronic Lymphocytic Leukemia

Radiation therapy is treatment with high-energy rays or particles to destroy cancer cells. Radiation therapy is usually not part of the main treatment for people with chronic lymphocytic leukemia (CLL), but it is used in certain situations.

- Radiation therapy can be used to treat symptoms caused by swollen internal organs (such as an enlarged spleen) pressing on other organs. For instance, pressure against the stomach may affect appetite. If these symptoms are not improved by chemotherapy, radiation therapy to help shrink the organ is often a good option.
- Radiation therapy can also be useful in treating pain from bone damage caused by leukemia cells growing in the bone marrow.
- Radiation therapy is sometimes given in low doses to the whole body, just before a stem cell transplant (see Stem Cell Transplant for Chronic Lymphocytic Leukemia).

External beam radiation therapy, in which a machine delivers a beam of radiation to a specific part of the body, is the type of radiation used most often for CLL. Before your treatment starts, the radiation team will take careful measurements to determine the correct angles for aiming the radiation beams and the proper dose of radiation. Radiation therapy is much like getting an x-ray, but the radiation is more intense. The procedure itself is painless. Each treatment lasts only a few minutes, although the setup time getting you into place for treatment usually takes longer.
Common short-term sideeffects of radiation therapy include:

- Skin changes in the treated area, which can vary from mild redness to like a burn
- **Fatigue**
- Low blood cell counts, increasing the risk of infection
- **Nausea and vomiting** (which is more common with radiation to the abdomen)
- Diarrhea (which is more common with radiation to the abdomen)

Ask your doctor what side effects you can expect.

You can learn more about radiation treatments in the Radiation Therapy section of our website.

- References

See all references for Chronic Lymphocytic Leukemia

Leukapheresis for Chronic Lymphocytic Leukemia

Sometimes very high numbers of leukemia cells in the blood cause problems with normal circulation. Chemotherapy may not lower the number of cells until a few days after the first dose. In the meantime, leukapheresis may be used before chemotherapy. In this procedure, your blood is passed through a special machine that removes white blood cells (including leukemia cells) and returns the rest of the blood cells and plasma back into the bloodstream.

For this procedure, you can lie in bed or sit in a reclining chair. Two IV lines are required the blood is removed through one IV, and then is returned to the body through the other IV. Sometimes, a single large catheter is placed in the neck or under the collar bone for the pheresis instead of using IV lines in the arms. This type of catheter is called a central line and has both IVs built in. Leukapheresis is not painful, but it can be hard to stay sitting or lying down in the same place for 2 or 3 hours. Also, sometimes calcium
levels can drop during the process, causing numbness and tingling (especially in the hands and feet and around the mouth) and sometimes painful muscle spasms. This can be treated easily with calcium.

Leukapheresis works quickly to get the number of leukemia cells down. However, without further treatment (like chemotherapy, monoclonal antibodies, or targeted therapy) to kill the cancer cells, the cell count will go back up again.

- References
See all references for Chronic Lymphocytic Leukemia

Supportive Care for Chronic Lymphocytic Leukemia

Supportive care for chronic lymphocytic leukemia (CLL) is aimed at helping with problems related to the cancer and its treatment. For example, some people with CLL have problems with infections or low blood counts. Although treating the CLL may help these over time, other therapies may be needed as well.

Treatments to prevent infections

Intravenous immunoglobulin (IVIG)

Some people with CLL don’t have enough antibodies (immunoglobulins) to fight infection. This can lead to repeated lung and/or sinus infections. The level of antibodies in the blood can be checked with a blood test, and if it is low, antibodies from donors can be given into a vein (IV) to raise the levels and help prevent infections. This is called intravenous immunoglobulin or IVIG. IVIG is often given once a month at first, but may be needed less often based on blood tests of antibody levels.

Antibiotics and anti-virals
Certain chemotherapy drugs (such as purine analogs see the chemotherapy section for details) and the antibody drug alemtuzumab (Campath) can raise your risk of certain infections such as CMV (a virus) and pneumonia caused by *Pneumocystis jiroveci*. You might be given an anti-viral drug like acyclovir or valacyclovir (Valtrex®) to lower the risk of CMV infections. To help prevent Pneumocystis pneumonia, a sulfa antibiotic is often given (trimethoprim with sulfamethoxazole, which is often known by the brand names Septra® or Bactrim®). Other treatments are available for people who are allergic to sulfa drugs.

Antibiotics and anti-viral drugs are also used to treat infections. Often, active infections require higher doses or different drugs than are used to prevent infections.

**Vaccines**

Experts recommend that people with CLL get the pneumonia vaccine every 5 years. They also recommend a yearly flu shot (influenza vaccine).

Vaccines that contain live viruses, such as the shingles vaccine (herpes zoster vaccine) should be avoided.

For more information on infections, including vaccines, see Infections in People With Cancer.

**Treatments for low blood counts**

CLL or its treatment can cause low red blood cell counts (anemia). Anemia can make you feel tired, light headed, or short of breath from walking. If anemia is causing symptoms, it can be treated with transfusions. These are often given on an outpatient basis.

If platelet counts get very low, it can lead to serious bleeding. Transfusing platelets can help prevent this.

In CLL, low red blood and platelet counts can also be caused by the cells being destroyed by abnormal antibodies. When antibodies cause low numbers of platelets, it is called *immune thrombocytopenia*. Before diagnosing this, the doctor often needs to check the bone marrow to make sure that there isn’t another cause for the low platelet counts. In immune thrombocytopenia, giving platelet transfusions doesn’t usually help increase the platelet counts much, if at all, because the antibodies just destroy the new platelets, too. This can be treated by drugs that affect the immune system, like corticosteroids, IVIG, and the antibody drug rituximab (Rituxan). Another option is to
remove the spleen, since after the antibodies stick to the platelets, they are actually destroyed in the spleen. Another option is a drug that tells the body to make more platelets, like eltrombopag (Promacta®) or romiplostim (Nplate®).

When antibodies cause low red blood cell counts, it is called autoimmune hemolytic anemia (AIHA). This also can be treated with drugs that affect the immune system, like corticosteroids, IVIG, and rituximab (Rituxan). Removing the spleen is also an option. If you develop AIHA while taking fludarabine (Fludara), the drug may be the cause, and so the fludarabine will be stopped.

- References

See all references for Chronic Lymphocytic Leukemia

Stem Cell Transplant for Chronic Lymphocytic Leukemia

The usual doses of chemotherapy drugs can reduce the number of leukemia cells in chronic lymphocytic leukemia and improve symptoms, but even if signs of leukemia go away, the disease often comes back later. Higher doses of these drugs might be more effective, but they often cannot be given because they could severely damage bone marrow, which is where new blood cells are formed. This could lead to life-threatening infections, bleeding, and other problems because of low blood cell counts.

A stem cell transplant (SCT) allows doctors to use higher doses of chemotherapy, sometimes along with radiation therapy, to treat the leukemia. After these treatments are finished, the patient receives a transplant of blood-forming stem cells to restore the bone marrow.

Blood-forming stem cells used for a transplant are obtained either from the blood (for a peripheral blood stem cell transplant, or PBSCT), from the bone marrow (for a bone marrow transplant, or BMT), or from umbilical cord blood. Bone marrow transplant was more common in the past, but it has largely been replaced by PBSCT.
It's not yet clear how helpful stem cell transplants are in patients with chronic lymphocytic leukemia (CLL). When these treatments are used, it is most often in clinical trials looking to test their effectiveness.

The 2 main types of stem cell transplants are allogeneic and autologous.

For an autologous transplant, the patient’s own stem cells are collected from the blood or bone marrow and then given back after treatment. The problem with that is that leukemia cells may be collected with the stem cells.

In an allogeneic transplant, the stem cells come from someone else (a donor). To lower the chance of complications, the donor needs to “match” the patient in terms of tissue type. Often, a close relative, such as a brother or sister is a good match. Less often, a matched unrelated donor may be found.

Because collecting the patient’s stem cells can also collect leukemia cells, allogeneic transplants are used more often in the treatment of CLL than autologous. Still, this type of transplant can cause severe or even life-threatening complications and side effects, and it is often not be a good option in people who are older or have other health problems.

For more information on stem cell transplants, see Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants).

- References
See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

**Typical Treatment of Chronic Lymphocytic Leukemia**

Treatment options for chronic lymphocytic leukemia (CLL) vary greatly, depending on the person’s age, the disease risk group, and the reason for treating (for example, which
symptoms it is causing). Many people live a long time with CLL, but in general it is very
difficult to cure, and early treatment hasn't been shown to help people live longer. 
Because of this and because treatment can cause side effects, doctors often advise 
waiting until the disease is progressing or bothersome symptoms appear, before 
starting treatment.

If treatment is needed, factors that should be taken into account include the patient’s 
age, general health, and prognostic factors such as the presence of chromosome 17 or 
chromosome 11 deletions or high levels of ZAP-70 and CD38.

**Initial treatment**

Patients who might not be able to tolerate the side effects of strong chemotherapy 
(chemo) are often treated with chlorambucil alone or with a monoclonal antibody like 
rituximab (Rituxan) or obinutuzumab (Gazyva). Other options include ibrutinib 
(Imbruvica), rituximab alone, or a corticosteroid like prednisone.

In stronger and healthier patients, there are many options for treatment. Commonly 
used treatments include:

- FCR: fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab
- Bendamustine (sometimes with rituximab)
- FR: fludarabine and rituximab
- CVP: cyclophosphamide, vincristine, and prednisone (sometimes with rituximab)
- CHOP: cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone
- Chlorambucil combined with prednisone, rituximab, obinutuzumab, or ofatumumab
- PCR: pentostatin (Nipent), cyclophosphamide, and rituximab
- Alemtuzumab (Campath)
- Fludarabine (alone)
- Ibrutinib (alone)

Other drugs or combinations of drugs may also be also used.

If the only problem is an enlarged spleen or swollen lymph nodes in one region of the 
body, localized treatment with low-dose radiation therapy may be used. Splenectomy 
(surgery to remove the spleen) is another option if the enlarged spleen is causing 
symptoms.

Sometimes very high numbers of leukemia cells in the blood cause problems with normal circulation. This is called *leukostasis*. Chemo may not lower the number of cells until a few days after the first dose, so before the chemo is given, some of the cells may
be removed from the blood with a procedure called leukapheresis. This treatment lowers blood counts right away. The effect lasts only for a short time, but it may help until the chemo has a chance to work. Leukapheresis is also sometimes used before chemo if there are very high numbers of leukemia cells (even when they aren’t causing problems) to prevent tumor lysis syndrome (this was discussed in the chemotherapy section).

Some people who have very high-risk disease (based on prognostic factors) may be referred for possible stem cell transplant (SCT) early in treatment.

**Second-line treatment of CLL**

If the initial treatment is no longer working or the disease comes back, another type of treatment may help. If the initial response to the treatment lasted a long time (usually at least a few years), the same treatment can often be used again. If the initial response wasn’t long-lasting, using the same treatment again isn’t as likely to be helpful. The options will depend on what the first-line treatment was and how well it worked, as well as the person’s health.

Many of the drugs and combinations listed above may be options as second-line treatments. For many people who have already had fludarabine, alemtuzumab seems to be helpful as second-line treatment, but it carries an increased risk of infections. Other purine analog drugs, such as pentostatin or cladribine (2-CdA), may also be tried. Newer drugs such as ofatumumab, ibrutinib, idelalisib (Zydelig), and venetoclax (Venclexta) may be other options.

If the leukemia responds, stem cell transplant may be an option for some patients.

Some people may have a good response to first-line treatment (such as fludarabine) but may still have some evidence of a small number of leukemia cells in the blood, bone marrow, or lymph nodes. This is known as minimal residual disease. CLL can’t be cured, so doctors aren’t sure if further treatment right away will be helpful. Some small studies have shown that alemtuzumab can sometimes help get rid of these remaining cells, but it’s not yet clear if this improves survival.

**Treating complications of CLL**

One of the most serious complications of CLL is a change (transformation) of the leukemia to a high-grade or aggressive type of non-Hodgkin lymphoma called diffuse large cell lymphoma. This happens in about 5% of CLL cases, and is known as Richter syndrome. Treatment is often the same as it would be for lymphoma (see Non-Hodgkin
Lymphoma for more information), and may include stem cell transplant, as these cases are often hard to treat.

Less often, CLL may transform to prolymphocytic leukemia. As with Richter syndrome, these cases can be hard to treat. Some studies have suggested that certain drugs such as cladribine (2-CdA) and alemtuzumab may be helpful.

In rare cases, patients with CLL may have their leukemia transform into acute lymphocytic leukemia (ALL). If this happens, treatment is likely to be similar to that used for patients with ALL.

Acute myeloid leukemia (AML) is another rare complication in patients who have been treated for CLL. Drugs such as chlorambucil and cyclophosphamide can damage the DNA of blood-forming cells. These damaged cells may go on to become cancerous, leading to AML, which is very aggressive and often hard to treat.

CLL can cause problems with low blood counts and infections. Treatment of these problems is discussed in Supportive Care in Chronic Lymphocytic Leukemia.

- References

See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

**Treating Hairy Cell Leukemia**

Hairy cell leukemia (HCL) tends to be slow growing. Patients without symptoms often don’t need to be treated right away, but they do need to have careful follow-up exams. These are done every few months to check for disease progression and appearance of symptoms. Some patients with HCL live for many years without having any symptoms or receiving any treatment.

Treatment may be advised for HCL patients with low blood cell counts, recurrent infections, or an enlarged spleen or lymph nodes. Treatment is most often with one of the purine analog drugs -- either cladribine (2-CdA) or pentostatin. Up to 80% to 90% of
patients respond to these drugs, and the responses last more than 5 years in most patients.

If the leukemia comes back again, it will most be often treated with a purine analog again. Often the same drug will be used as was given the first time, especially if the leukemia stayed in remission for a long time. Sometimes the monoclonal antibody rituximab (Rituxan) will be given as well.

In rare cases, HCL may not respond to chemotherapy. Rituximab or interferon-alfa, a type of biologic therapy, may be helpful. If a patient is uncomfortable because of an enlarged spleen, removing the spleen by surgery (splenectomy) can often help relieve pain or other symptoms.

- References
See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.

2016 Copyright American Cancer Society

For additional assistance please contact your American Cancer Society
1-800-227-2345 or www.cancer.org
After Treatment

Living as a CLL Survivor

For many people, cancer treatment often raises questions about next steps as a survivor.

- What Happens After Treatment for Chronic Lymphocytic Leukemia?
- Lifestyle Changes During and After Treatment for Chronic Lymphocytic Leukemia
- How About Your Emotional Health During and After Treatment for Chronic Lymphocytic Leukemia?

Cancer Concerns After Treatment

Treatment may remove or destroy the cancer, but it is very common to have questions about cancer coming back or treatment no longer working.

- Can I Get Another Cancer After Having Chronic Lymphocytic Leukemia?
- If Treatment for Chronic Lymphocytic Leukemia Stops Working

What Happens After Treatment for Chronic Lymphocytic Leukemia?

Chronic lymphocytic leukemia (CLL) is rarely able to be cured. Still, most people live for many years with the disease. Some people with CLL can live for years without treatment, but most eventually need to be treated. Most people with CLL are treated on and off for years. Treatment may stop for a while, but it never really ends. Learning to live with cancer that does not go away can be difficult and very stressful. See Managing Cancer As A Chronic Illness for more about this.
Follow-up care

Before, during, and after treatment, your doctors will want to watch you closely. It is very important to go to all of your follow-up appointments. During these visits, your doctors will ask questions about any problems you may have and may do exams and lab tests or x-rays and scans to look for signs of cancer or treatment side effects. Almost any cancer treatment can have side effects. Some may last for a few weeks to months, but others can last the rest of your life. This is the time for you to talk to your cancer care team about any changes or problems you notice and any questions or concerns you have. It is important that you report any new symptoms to the doctor right away so that the cause can be found and treated, if needed.

Checkups may include careful physical exams, blood tests, and other tests as needed. A benefit of follow-up care is that it gives you a chance to discuss questions and concerns that can arise.

Treatment of CLL is not expected to cure the disease. This means that even if there are no signs of leukemia after treatment (known as a complete remission), the leukemia is likely to come back again (recur) at some point. Further treatment will depend on what treatments you've had before, how long it's been since treatment, and your overall health. For more information on how recurrent CLL is treated, see Treating Chronic Lymphocytic Leukemia. For more general information on dealing with a recurrence, see Understanding Recurrence.

It is important to keep health insurance. Tests and doctor visits cost a lot, and even though no one wants to think of their cancer coming back, this could happen.

Most people with CLL do not have normally functioning immune systems, which may raise their risk for certain infections. Some treatments for CLL, such as alemtuzumab (Campath) and many chemotherapy drugs, may also raise this risk. Your doctor may recommend vaccines or other medicines to help prevent or control certain infections.

People with CLL are also at increased risk of developing a second cancer. At least some of this increased risk may be due to the effects of CLL on the immune system. Treatments for CLL may also raise the risk of some cancers. The most common second cancers in people with CLL are skin and lung cancers, although other types of leukemia, lymphoma, and other blood cancers are also possible. It is important to be aware of this increased risk and to report any possible symptoms to your doctor right away.

Seeing a new doctor
At some point after your cancer diagnosis and treatment, you may find yourself seeing a new doctor who does not know anything about your medical history. It is important that you be able to give your new doctor the details of your diagnosis and treatment. Gathering these details soon after treatment may be easier than trying to get them at some point in the future. Make sure you have the following information handy:

- A copy of your pathology report(s) from any biopsies or surgeries
- If you had surgery, a copy of your operative report(s)
- If you were in the hospital, a copy of the discharge summary that doctors prepare when patients are sent home
- If you had radiation therapy, a copy of the treatment summary
- If you were treated with drugs (such as chemotherapy, monoclonal antibodies, or targeted therapy), a list of the drugs, drug doses, and when you took them

The doctor may want copies of this information for his records, but always keep copies for yourself.

- References

See all references for Chronic Lymphocytic Leukemia

Can I Get Another Cancer After Having Chronic Lymphocytic Leukemia?

Cancer survivors can be affected by a number of health problems, but often their greatest concern is facing cancer again. If a cancer comes back after treatment it is called a “recurrence.” But some cancer survivors may develop a new, unrelated cancer later. This is called a “second cancer.” No matter what type of cancer you have had, it is still possible to get another (new) cancer, even after surviving the first.

Unfortunately, being treated for cancer doesn’t mean you can’t get another cancer. People who have had cancer can still get the same types of cancers that other people get. In fact, certain types of cancer and cancer treatments can be linked to a higher risk
of certain second cancers.

People with chronic lymphocytic leukemia (CLL) can get any type of second cancer, but they have an increased risk of:

- Salivary gland cancer
- Cancer of the lip
- Cancers of the nose and nasal cavity
- Cancer of the larynx
- Lung cancer
- Colon cancer
- Hodgkin lymphoma
- Kaposi sarcoma
- Melanoma of the skin
- Kidney cancer

Women with CLL also have an increased risk of rectal cancer.

**Follow-up**

People with CLL need to see their doctors regularly. They can have CLL for a long time without needing treatment. Let your doctor know if you have any new symptoms or problems. These may be from the CLL and mean that treatment is needed, or they may be from some other cancer or disease. Treatment doesn’t cure this cancer, but can cause it to regress or go away for a time. Then, if the leukemia comes back or worsens, treatment may begin again.

All people with CLL should avoid tobacco smoke, as smoking increases the risk of many cancers and might further increase the risk of some of the second cancers seen in patients with CLL.

To help maintain good health, survivors should also:

- Achieve and maintain a healthy weight
- Adopt a physically active lifestyle
- Consume a healthy diet, with an emphasis on plant foods
- Limit consumption of alcohol to no more than 1 drink per day for women or 2 per day for men

These steps may also lower the risk of some cancers.
See Second Cancers in Adults for more information about causes of second cancers.

- References
See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please contact permissionrequest@cancer.org.

Lifestyle Changes During and After Treatment for Chronic Lymphocytic Leukemia

You can't change the fact that you have had cancer. What you can change is how you live the rest of your life – making choices to help you stay healthy and feel as well as you can. This can be a time to look at your life in new ways. Maybe you are thinking about how to improve your health over the long term. Some people even start during cancer treatment.

Making healthier choices

For many people, a diagnosis of cancer helps them focus on their health in ways they may not have thought much about in the past. Are there things you could do that might make you healthier? Maybe you could try to eat better or get more exercise. Maybe you could cut down on alcohol, or give up tobacco. Even things like keeping your stress level under control may help. Now is a good time to think about making changes that can have positive effects for the rest of your life. You will feel better and you will also be healthier.

You can start by working on those things that worry you most. Get help with those that are harder for you. For instance, if you are thinking about quitting smoking and need help, call the American Cancer Society for information and support. This tobacco cessation and coaching service can help increase your chances of quitting for good.
Eating better

Eating right can be hard for anyone, but it can get even tougher during and after cancer treatment. Treatment may change your sense of taste. Nausea can be a problem. You may not feel like eating and lose weight when you don't want to. Or you may have gained weight that you can't seem to lose. All of these things can be very frustrating.

If treatment caused weight changes or eating or taste problems, do the best you can and keep in mind that these problems usually get better over time. You may find it helps to eat small portions every 2 to 3 hours until you feel better. You may also want to ask your cancer team about seeing a dietitian, an expert in nutrition who can give you ideas on how to deal with these treatment side effects.

One of the best things you can do after cancer treatment is put healthy eating habits into place. You may be surprised at the long-term benefits of some simple changes, like increasing the variety of healthy foods you eat. Getting to and staying at a healthy weight, eating a healthy diet, and limiting your alcohol intake may lower your risk for a number of types of cancer, as well as having many other health benefits.

Rest, fatigue, and exercise

Extreme tiredness, called fatigue, is very common in people treated for cancer. This is not a normal tiredness, but a "bone-weary" exhaustion that doesn't get better with rest. For some people, fatigue lasts a long time after treatment, and can make it hard for them to exercise and do other things they want to do. But exercise can help reduce fatigue. Studies have shown that patients who follow an exercise program tailored to their personal needs feel better physically and emotionally and can cope better, too.

If you were sick and not very active during treatment, it is normal for your fitness, endurance, and muscle strength to decline. Any plan for physical activity should fit your own situation. Someone who has never exercised will not be able to take on the same amount of exercise someone who plays tennis twice a week. If you haven't exercised in a few years, you will have to start slowly – maybe just by taking short walks. You can read more in Nutrition and Physical Activity During and After Cancer Treatment: Answers to Common Questions.

Talk with your health care team before starting anything. Get their opinion about your exercise plans. Then, try to find an exercise buddy so you're not doing it alone. Having family or friends involved when starting a new exercise program can give you that extra boost of support to keep you going when the push just isn't there.
If you are very tired, you will need to balance activity with rest. It is OK to rest when you need to. Sometimes it's really hard for people to allow themselves to rest when they are used to working all day or taking care of a household, but this is not the time to push yourself too hard. Listen to your body and rest when you need to. For more information on dealing with fatigue, see *Fatigue in People With Cancer* and *Anemia in People With Cancer*.

Keep in mind that exercise can improve your physical and emotional health.

- It improves your cardiovascular (heart and circulation) fitness.
- Along with a good diet, it will help you get to and stay at a healthy weight.
- It makes your muscles stronger.
- It reduces fatigue and helps you have more energy.
- It can help lower anxiety and depression.
- It can make you feel happier.
- It helps you feel better about yourself.

And long term, we know that getting regular physical activity plays a role in helping to lower the risk of some cancers, as well as having other health benefits.

- **References**
  
  See all references for *Chronic Lymphocytic Leukemia*

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

________________________________________

American Cancer Society medical information is copyrighted material. For reprint requests, please contact permissionrequest@cancer.org.

**How About Your Emotional Health During and After Treatment for Chronic Lymphocytic Leukemia?**

When treatment is over (even for a while), you may find yourself overcome with many different emotions. This happens to a lot of people. You may have been going through so much during treatment that you could only focus on getting through each day. Now it may feel like a lot of other issues are catching up with you.
You may find yourself thinking about death and dying. Or maybe you're more aware of the effect the cancer has on your family, friends, and career. You may take a new look at your relationship with those around you. Unexpected issues may also cause concern. For instance, as you feel better and have fewer doctor visits, you will see your health care team less often and have more time on your hands. These changes can make some people anxious.

Almost everyone who has been through cancer can benefit from getting some type of support. You need people you can turn to for strength and comfort. Support can come in many forms: family, friends, cancer support groups, church or spiritual groups, online support communities, or one-on-one counselors. What's best for you depends on your situation and personality. Some people feel safe in peer-support groups or education groups. Others would rather talk in an informal setting, such as church. Others may feel more at ease talking one-on-one with a trusted friend or counselor. Whatever your source of strength or comfort, make sure you have a place to go with your concerns.

The cancer journey can feel very lonely. It is not necessary or good for you to try to deal with everything on your own. And your friends and family may feel shut out if you do not include them. Let them in, and let in anyone else who you feel may help. If you aren’t sure who can help, call your American Cancer Society at 1-800-227-2345 and we can put you in touch with a group or resource that may work for you. You may also want to read Distress in People with Cancer.

- References
See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

If Treatment for Chronic Lymphocytic Leukemia Stops Working

When chronic lymphocytic leukemia (CLL) keeps growing or comes back after one treatment, another treatment plan is likely to help, at least for a while. But when a person has tried many different treatments and the cancer has not gotten any better, the
cancer tends to become resistant to all treatment. If this happens, it’s important to weigh the possible limited benefits of a new treatment against the possible downsides. Everyone has their own way of looking at this.

This is likely to be the hardest part of your battle with cancer when you have been through many medical treatments and nothing's working anymore. Your doctor may offer you new options, but at some point you may need to consider that treatment is not likely to improve your health or change your outcome or survival.

If you want to continue to get treatment for as long as you can, you need to think about the odds of treatment having any benefit and how this compares to the possible risks and side effects. In many cases, your doctor can estimate how likely it is the cancer will respond to treatment you are considering. For instance, the doctor may say that more chemo or radiation might have about a 1% chance of working. Some people are still tempted to try this. But it is important to think about and understand your reasons for choosing this plan.

No matter what you decide to do, you need to feel as good as you can. Make sure you are asking for and getting treatment for any symptoms you might have, such as nausea or pain. This type of treatment is called palliative care.

Palliative care helps relieve symptoms, but is not expected to cure the disease. It can be given along with cancer treatment, or can even be cancer treatment. The difference is its purpose - the main purpose of palliative care is to improve the quality of your life, or help you feel as good as you can for as long as you can. Sometimes this means using drugs to help with symptoms like pain or nausea. Sometimes, though, the treatments used to control your symptoms are the same as those used to treat cancer. For instance, radiation might be used to help relieve bone pain caused by cancer that has spread to the bones. Or chemo might be used to help shrink a tumor and keep it from blocking the bowels. But this is not the same as treatment to try to cure the cancer. You can learn more about the changes that occur when curative treatment stops working, and about planning ahead for yourself and your family, in Nearing the End of Life and Advance Directives.

At some point, you may benefit from hospice care. This is special care that treats the person rather than the disease; it focuses on quality rather than length of life. Most of the time, it is given at home. Your cancer may be causing problems that need to be managed, and hospice focuses on your comfort. You should know that while getting hospice care often means the end of treatments such as chemo and radiation, it doesn't mean you can't have treatment for the problems caused by your cancer or other health conditions. In hospice the focus of your care is on living life as fully as possible and feeling as well as you can at this difficult time. You can learn more in Hospice Care.
Staying hopeful is important, too. Your hope for a cure may not be as bright, but there is still hope for good times with family and friends—times that are filled with happiness and meaning. Pausing at this time in your cancer treatment gives you a chance to refocus on the most important things in your life. Now is the time to do some things you’ve always wanted to do and to stop doing the things you no longer want to do. Though the cancer may be beyond your control, there are still choices you can make.

- **References**
  
  See all references for Chronic Lymphocytic Leukemia

Last Medical Review: January 6, 2015 Last Revised: April 11, 2016

American Cancer Society medical information is copyrighted material. For reprint requests, please contact permissionrequest@cancer.org.

2016 Copyright American Cancer Society

For additional assistance please contact your American Cancer Society
1-800-227-2345 or www.cancer.org